Real-world data (RWD) has been defined as data generated outside of traditional randomized clinical trials (RCTs). Though RWD has received increasing attention from regulatory authorities and professional societies, dividing evidence into that derived from 'real-world' vs. 'non-real-world' sources provides only one element of a much larger framework for evidence evaluation. Evidence should be evaluated on the source of the data, the method of treatment allocation (whether any intervention being evaluated was assigned or simply observed as used in practice) and the context in which the evidence was generated (overall study design). Under this framework, RWD refers only to data source, and a study incorporates RWD when it primarily uses data collected for non-research purposes, such as insurance claims data or the electronic health record, regardless of study design. Separation of study design, data source, and context enables parallel evaluation of two critical elements: (i) whether a study can support claims of causal inference, which can be assured with a high degree of confidence only in studies where patients are assigned treatments by protocol; and (ii) whether the study population and clinical context mirror clinical practice, a strength of observational studies using data from clinical practice or administrative claims. In this review, we describe the strengths and weaknesses of observational and non-observational studies, and studies involving RWD and non-RWD, through the lens of anticoagulation for atrial fibrillation (AF). Observational studies employing RWD are useful for describing how oral anticoagulants are used in clinical practice, but generally cannot be used to make claims regarding comparative treatment effects. Questions regarding treatment effect generally are best answered through an RCT, and additional pragmatic RCTs are needed to compare different antithrombotic agents for the prevention of thrombotic events in AF.
Introduction
Evidence to guide clinical decision-making has traditionally come from data collected specifically for research purposes, including disease-specific registries and traditional randomized controlled trials (RCTs). These data sources have a number of advantages leading to high internal validity, often including well-defined inclusion and exclusion criteria, near-complete data collection, and event adjudication according to standardized definitions. However, RCTs have grown increasingly costly and complex, and their generalizability and external validity have been questioned. 1, 2 'Real-world data' (RWD) has potential to overcome some of the limitations of traditional RCTs by leveraging data already collected for other reasons to enable efficient study design and generalization of findings to broad and less selected patient populations, helping provide patients, caregivers, and providers with the answers to However, it is important to highlight the use of the term conventional in the EMA's definition. Similarly, the U.S. Food and Drug Administration (FDA) defines RWD as 'data collected from sources outside of traditional clinical trials', and its more expansive definition notes that RWD includes 'large simple trials, or pragmatic clinical trials', in addition to 'prospective observational or registry studies, retrospective database studies, case reports, administrative and healthcare claims, electronic health records, data obtained as part of a public health investigation or routine public health surveillance, and registries'. 6 U.S. Congress specifically amended the definition of RWD in the 21st Century Cares Act to data 'derived from sources other than traditional clinical trials', inserting traditional in place of randomized.
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The term RWD, as defined by regulatory agencies and legislative authorities, is intentionally so broad as to be nearly meaningless by itself as a mode of evidence characterization. Nevertheless, 'real-world studies', whether observational or interventional in design, are often touted in the medical literature and lay press as providing true clinical proof of effectiveness, in counterpoint to 'unrealistic' RCTs. However, this simple dichotomy between RWD and RCTs is not ultimately a useful system for evidence characterization or evaluation. From the perspective of a patient, practicing clinician, researcher, guidelines author, or regulatory agency, two of the key questions critical to evaluating evidence are: (i) Is the patient population studied representative of patients with the disease? and (ii) Does the study support claims of causality? Answering these questions requires an understanding of both data source and study design. Whether a study incorporates RWD, which we propose defining narrowly as data collected for non-research purposes, is useful only for understanding representativeness. Study design remains critical for understanding whether evidence can support claims of causality. Even with the rise of big data and advances in statistical methods, in most cases, the best way to conclusively determine whether there is a causal relationship between an intervention and an outcome is to randomize, and randomization is only possible in studies that assign treatments to patients as part of a research protocol.
To better serve the needs of evidence consumers, evidence should be characterized in terms of two independent questions: (i) whether treatments are assigned or determined by usual care (interventional vs. observational study design) and (ii) whether data are collected specifically for research or are collected for other reasons and then repurposed (non-RWD vs. RWD source) (Take home figure) . Under this framework, RWD includes data collected for non-research purposes, including insurance claims, regulatory surveillance, electronic health record data, and data collected from patients' homes, work, or school for the purpose of clinical care or maintaining health. By contrast, data collected solely for research purposes, as in disease-specific registries or traditional clinical trials, is non-RWD. Individual studies can thus be categorized as observational studies using RWD, observational studies using non-RWD, interventional studies using RWD, and interventional studies using non-RWD. In a growing number of cases, when diseasespecific registries are linked to insurance claims data to facilitate the collection of intermediate-and long-term outcomes, these studies involve both RWD and non-RWD.
Studies of each type have specific strengths and weaknesses, and the key question evaluators must ask is whether the data source and methods used were optimal for answering the question posed. Outside of these categories, studies may be characterized by the burden they place on participants through requirement for informed consent or multiple study visits; studies placing less burden on patients-such as the large simple trials of thrombolysis in acute myocardial infarction (MI) conducted in the 1980s and early 1990s, which collected follow-up data on a postcard, 11, 12 or modern quality improvement registries in the U.S. that avoid the need for informed consent 13 -will generate more generalizable study data irrespective of data provenance or study design.
The last 6 years of research surrounding anticoagulation for atrial fibrillation (AF) provides an illustrative lens to examine the potential and pitfalls of RWD. Pivotal clinical trials conducted in the 1980s and 1990s established the clear benefit of the vitamin K antagonist (VKA) warfarin, as compared with both aspirin and placebo, for the prevention of stroke in patients with AF.
14 Despite reducing the risk of stroke by more than 60% compared with placebo and 40% compared with aspirin, 14, 15 warfarin's unpredictable pharmacodynamics, narrow therapeutic window, increased risk of bleeding (especially intracranial haemorrhage), and need for frequent office visits and blood draws to monitor anticoagulation led to the development of the non-VKA oral anticoagulants (NOACs). All four NOACs-dabigatran, a direct thrombin inhibitor, and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban-were approved in the U.S. and Europe within the last decade on the basis of pivotal RCTs demonstrating non-inferiority compared with warfarin in stroke prevention. [16] [17] [18] [19] Because the four available NOACs were developed roughly concurrently and earned regulatory approval and professional society guideline recommendation on the basis of non-inferiority compared with warfarin, 20, 21 no prospective RCT has compared them in a head to head fashion. However, dozens of observational studies using both RWD and non-RWD have evaluated patterns of AF management and NOAC use and performed comparative effectiveness analyses of the various NOACs.
'Real-world' and non-real-world data sources
In the arena of anticoagulation for AF, there have been traditional RCTs, non-randomized single-arm cohort studies, prospective registries, and retrospective analyses of insurance claims and electronic health records (Box 1 and Table 1) . Though no pragmatic RCTs have been conducted involving the use of NOACs for anticoagulation in AF, pragmatic RCTs are an important component of the data universe and will be discussed. Each data source has advantages and disadvantages ( Table 2) .
Non-'real-world' data sources
Study designs employing non-RWD include traditional RCTs, nonrandomized single-arm cohort studies, and prospective registries. [22] [23] [24] [25] [26] Traditional RCTs' use of rigid protocol-based follow-up, with routine assessment of treatment adherence, in a limited patient population also raises questions about their generalizability to routine clinical practice. The enormous expense of traditional RCTs also limits follow-up duration and sample size, reducing their ability to detect rare adverse events. Non-randomized single-arm cohort studies, which enrol patients taking a certain medication or in whom a certain device has been implanted, and prospective registries, which enrol patients with a certain disease, are observational study designs using non-RWD which share many of their strengths and weaknesses. They are often designed and conducted to better understand the safety and efficacy of medications or devices outside of the controlled environment of RCTs. They thus usually have broad inclusion criteria and few exclusion criteria, and screen consecutive patients to enrol a representative sample of patients, including many patients who may not have been eligible for clinical trials. Enrolment is prospective, and trained research personnel determine whether patients meet inclusion criteria and collect baseline data, which reduces missing data elements. Follow-up for adverse events and major clinical outcomes is often less intrusive than in clinical trials, which may improve the likelihood that patients will consent or remain in follow-up. Though less intrusive follow-up data collection may increase the generalizability of findings, it may come at the cost of less accurate and reliable data, including the underreporting of adverse outcomes. 27 Less intrusive follow-up also reduces the cost per patient to perform these observational studies, enabling enrolment of more patients with longer follow-up durations, which provides a basis for collecting data on long-term safety and incidence of rare adverse events. A European Society of Cardiology position paper advocated for the use of observational data to supplement RCT evidence in this way to streamline cardiovascular drug development and help patients receive therapies earlier in the development process. 28 As part of its approval of rivaroxaban, the EMA required the manufacturer to conduct a long-term observational study as part of the post-approval plan. 29 Weaknesses of these study designs include the need to obtain informed consent and use of specialized sites. The need to obtain informed consent is a barrier to enrolment that may make the sample less than fully representative if it is not incorporated smoothly into clinical practice. In addition, participation in a research study may alter patient and provider behaviour (Hawthorne effect) and make the results (particularly with regard to adherence, persistence, medication choices, or dosing) less representative of truly routine clinical practice. This limitation is present in any study that requires informed consent, whether it uses RWD or non-RWD, including RCTs, non-randomized single-arm cohort studies, prospective registries, or pragmatic clinical trials, and limits generalizability of findings. Barring changes to regulations or care processes that enable investigators to obtain informed consent in close to 100% of approached patients, only studies that do not require informed consent, which are almost always retrospective, are able to capture a fully representative population. Some investigators have been able to avoid informed consent altogether by using probabilistic methods to anonymously link baseline data collected in quality improvement registries to insurance claims for ascertainment of long-term outcomes, taking advantage of the general acceptance that anonymized data can be analysed without consent. 30 
Real-world data sources
Study designs employing 'real-world' data sources include retrospective cohort studies and non-traditional RCTs.
Retrospective cohort studies most frequently use insurance claims and/or electronic health record data. Studies using insurance claims most frequently use billing claims to identify a cohort of interest, and then follow the patients forward for the occurrence of key clinical outcomes, defined again by billing codes for hospitalizations or other administrative records. Studies using electronic health record data use similar processes, though some smaller studies may manually extract baseline and follow-up data. The major strength of a retrospective cohort design is the ability to assemble a large, representative cohort, since there is no need for consent or follow-up, and all eligible patients are enrolled. Since neither patients nor physicians know about the study at the time care is delivered, there is no possibility that they will modify their behaviour due to their participation. Furthermore, since data are collected as a part of routine clinical care, costs are substantially less than for prospective studies or registries. Data on hospital or payer costs may also be available to facilitate economic analyses. Limitations of this type of study design include the use of billing codes to identify and describe patients and • outcomes rather than information reported by patients or trained investigators. This results in an inability to identify contraindications and other rationale for treatment decisions, and an inability to assess the quality of anticoagulation in warfarin-treated patients. In addition, event ascertainment using administrative claims data relies on physician billing, which is non-systematic and unblinded, and may be incomplete, inaccurate, or biased. 27 Non-traditional RCTs include both registry-based RCTs and pragmatic clinical trials. These trials are distinguished from traditional RCTs by their leveraging of data collected for non-research purposes. Modern pragmatic clinical trials capture data collected in the course of routine care (such as insurance claims or electronic health record data) or rely on patients to enter their own clinical data, and registry-based trials leverage data collected in quality improvement registries. Both designs typically have broad inclusion criteria with minimal exclusion criteria, open-label treatment assignment, and limited site monitoring. Trial procedures and endpoint ascertainment are either embedded in routine clinical care or facilitated by direct patient participation in the research process. 31 These features make pragmatic and registry-based RCTs less complex and costly than traditional RCTs. However, these features also lead to the limitations of pragmatic RCTs: Limited monitoring and safety reporting may prevent ascertainment of important safety signals, especially unexpected ones, and event ascertainment from patient-reported and administrative sources raises the same data integrity questions as in retrospective cohort studies. 27, 32, 33 However, application of quality by design principles 34 to clinical research suggests that claims data need not be perfect, but only good enough to achieve the goals of the study; for situations where a therapy's safety profile is well-established, missing safety or efficacy data is unlikely to appreciably change trial interpretation, pragmatic RCTs may be useful. Pragmatic RCTs also require informed consent, which may limit external validity, though some groups have been able to achieve nearly 100% participation through the use of novel methods, including electronic consent, combining written informed consent for research with informed consent for clinical procedures, and the use of verbal informed consent prior to study procedures with written informed consent after. 31, 35, 36 Large, simple traditional RCTs, like the thrombolytic trials conducted in patients with acute MI in the late 1980s and early 1990s, 11, 12 collect data outside of the scope of clinical care, but lack the close monitoring and extensive data collection that drive the high cost and complexity of traditional clinical trials. 37 Though these trials have historically used non-RWD, their strengths and weaknesses closely parallel non-traditional clinical trials, and future large simple trials are likely to combine RWD with large simple trial procedures.
Matching data source and methodology to research question
The optimal data source and methodology to use in a study are driven largely by the type of question investigators seek to answer ( Figure 1) . Investigators should only use data sources and study methodology appropriate for their questions, and consumers of the medical literature should critically appraise the data source and methods used by authors and the appropriateness of claims made. It is critical to contextualize the strengths and limitations of each data source and study methodology in terms of the goals of the study, applying the quality by design framework to research study design.
Patterns of use
Observational studies, using both data collected for specifically for research purposes and repurposed administrative data, have proven particularly useful for describing trends in the use of various antithrombotic therapies for patients with AF. The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) enrolled patients from 42 countries in North America, South America, Europe, Asia, Africa, and the Middle East with AF diagnosed within the previous 3 months and a CHADS 2 -VASc score > _1; investigators used this registry to describe patterns of antithrombotic therapy prescribed to 10 000 patients from 2011-14. 38 Overall, 32% of patients were prescribed VKAs, 48% were prescribed a NOAC, 12% were prescribed aspirin alone, and 8% were prescribed no antithrombotic treatment. In Europe, 38% were prescribed warfarin, 53% a NOAC, 5% aspirin alone, and 4% no antithrombotic therapy. Data regarding patterns of medication use can only be obtained from a purely observational study, since in any clinical trial, treatment is assigned by protocol, and choices are not left to the discretion of the treating physician and patients. Registries enable description of treatment patterns; the several AF registries with global scope enable this description on a global scale. Registries also offer the advantage of a well-defined patient population; the GLORIA-AF registry was able to enrol patients with newly-diagnosed AF. However, although treatment choices are left up to the physician's discretion in registries and the patient population is well-defined, the findings may not be entirely generalizable. Physicians, practices, and patients voluntarily choose to participate in registries, and these volunteers may differ in systematic ways from the unselected population of physicians and practices caring for patients with AF. 39 Retrospective cohort studies using administrative data do not have this limitation, and have demonstrated different results. In a study using Danish nationwide administrative data, investigators identified anticoagulation-naïve patients initiating oral anticoagulation from 2011-13, concurrent with the enrolment of patients into GLORIA-AF. Of 18 611 patients, 53% started a VKA and 46% started a NOAC. 40 Compared with European patients in GLORIA-AF, a greater proportion of patients in this RWD source were started on a VKA and a lower proportion were started on a NOAC. Physicians voluntarily participating in a registry seeking to study anticoagulation in patients with AF are likely to have greater interest in this patient population, and it is unsurprising that they more frequently used newly-introduced medications. The principal limitation of using RWD for this type of study is an inability to sharply define the population; rather than having physicians identify patients with newlydiagnosed non-valvular AF for enrolment (as in a registry), the Danish investigators applied billing codes as inclusion and exclusion criteria.
Dosing
Observational data are also optimal for describing dosing of medications in clinical practice. Non-VKA oral anticoagulants labels include instructions for dose reduction in certain situations, based on doses used in pivotal clinical trials, and all NOACs are available at multiple 42 A Canadian group obtained similarly detailed data through a retrospective chart audit, finding that 7% of patients prescribed NOACs were underdosed and 4% were overdosed. 43 However, these analyses again illustrate the limitation of selection bias in registries and some retrospective chart audits: physicians and patients participating in registries and hospital systems conducting chart audits are likely to be more motivated to learn about the disease process, and thus more knowledgeable regarding proper treatment patterns than non-participating physicians and systems. In other retrospective studies, inappropriate dosing rates were considerably higher, 44, 45 and claims data have shown a higher proportion of patients receiving dose-reduced NOACs than would be expected based on rates of chronic kidney disease. 46 
Adherence and persistence
Observational studies are also the best method for evaluating adherence to and persistence with medications. Traditional RCTs enrol patients more likely to adhere to medication, and frequent contact with the investigative team makes patients more likely to remain adherent, so these traditional RCTs are likely to report higher adherence and persistence than that seen in routine clinical practice.
Non-randomized single-arm cohort studies may have the same issues, leaving registries and administrative data as the best sources of data regarding adherence and persistence.
In an analysis of patients with treatment-naïve AF in a U.S. administrative database, 57% of apixaban initiators were adherent. 47 In a separate analysis of 21 225 U.S. patients receiving NOACs (not just those newly started), adherence was 70% in patients treated with apixaban. 48 The discrepancy in adherence between these two studies highlights the importance of understanding how cohorts are formed, especially with studies using administrative data. Importantly, adherence in observational RWD is much lower than observed in RCTs; 94% of patients were observed to take > _80% of their assigned apixaban tablets in Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), the pivotal RCT evaluating apixaban in patients with AF. 49 Persistence with NOACs has also been described in multiple observational RWD sources. In a Swedish database including 16 096 patients with non-valvular AF newly started on oral anticoagulation, 78% of patients starting on rivaroxaban persisted with this medication at 1 year. 50 In a comparable U.K. registry, persistence with any NOAC was 83% at 1 year. 51 These findings are in line with those from the non-randomized observational cohort study Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS), which showed persistence with rivaroxaban of 80% at 1 year. 29 Outcomes on a specific medication
Pivotal RCTs of the NOACs demonstrated the relative efficacy and safety of NOACs and warfarin among patients with AF at risk for Figure 1 When evaluating studies, it is critical to determine whether the data source and study design are appropriate for the question researchers intend to answer and the claims they make. [16] [17] [18] [19] However, many patients that might receive NOACs in clinical practice were not represented in the pivotal clinical trials, and so the incidence of stroke and major bleeding in these trials may not represent the true incidence in clinical practice. Of patients with AF and CHADS 2 -VASc > _1 (intermediate to high risk of stroke) in the UK, between 51 and 68% met all inclusion and no exclusion criteria for each of the pivotal NOAC trials. 2 Conversely, among patients on haemodialysis for end-stage renal disease, none of whom were included in pivotal NOAC clinical trials, 12% of patients requiring anticoagulation are started on NOACs. 52 Observational data thus provides important context regarding outcomes on these medications in the cohort of patients actually taking them, and has generated hypotheses for ongoing RCTs. 53, 54 One way to answer this type of question is a non-randomized, single-arm cohort study. In XANTUS, for example, the stroke or systemic embolism rate was 0.8 per 100 patient-years, and the major bleeding rate was 2.1 per 100 patient-years, compared with 1.7 and 3.6, respectively, in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), the pivotal RCT leading to rivaroxaban's approval. 29 These data are consistent with the fact that ROCKET AF enrolled a higher risk patient population than XANTUS due to strict inclusion criteria intended to enrich for high-risk patients, and the incidence of stroke and major bleeding in XANTUS may better reflect outcomes on rivaroxaban in routine clinical practice. 16, 29 However, non-randomized single-arm cohort studies still require informed consent, and compensate physicians for enrolment, which will result in the enrolment of a population that is not exactly representative of routine clinical practice.
Investigators have also described outcomes among patients taking each NOAC using administrative data. In a French administrative database, for example, the rate of hospitalization for stroke or systemic embolism among patients with non-valvular AF newly started on rivaroxaban was 1.4 per 100 patient-years and the rate of hospitalization for bleeding was 3.7 per 100 patient-years, reasonably close to the ROCKET AF results. 16, 55 Though use of RWD avoids the biases associated with enrolling a selected patient population, its reliance on insurance claims data requires the use of different endpoints than those used in traditional RCTs: The endpoints in the French study described above were hospitalization for stroke or major bleeding, rather than stroke or major bleeding alone; patients who died of a stroke or major bleeding event prior to being hospitalized, for example, are not captured by this definition. Furthermore, study designs other than traditional clinical trials devote fewer resources to event ascertainment, which may result in failure to capture a portion of clinical events.
Comparative treatment effect
Observational RWD from administrative data sources has also been used by investigators in an attempt to compare outcomes for patients taking various NOACs and VKAs. The results of these studies have been inconsistent, with some showing fewer embolic and bleeding events with NOACs, and others showing no difference between NOACs and warfarin ( Figure 2) . 46, [55] [56] [57] [58] [59] [60] These studies all contradict, at least in part, the results of large, well-conducted clinical trials with randomized treatment allocation, which showed lower rates of major bleeding in patients treated with all NOACs compared with warfarin, and numerically lower rates of stroke or systemic embolism with apixaban, rivaroxaban, and higher-dose dabigatran. [16] [17] [18] Other observational studies have used RWD sources to compare outcomes between cohorts of patients taking two or more NOACs. Comparative effectiveness analyses using observational designs need to be interpreted with caution. There are numerous examples in the cardiology literature of results generated from the study of observational data being later contradicted by well-conducted RCTs, including revascularization in patients with stable ischaemic heart disease, and the use of vitamin E and hormone replacement therapy for primary prevention of cardiac events. [64] [65] [66] Specifically in the case of comparative effectiveness studies undertaken using RWD, there are questions related to cohort development, event ascertainment, quality of warfarin anticoagulation, and dosing of NOACs. 67 More broadly, observational research, whether using RWD or non-RWD, is poorly suited to determine causality because of the inability to exclude confounding from unmeasured covariates, despite the numerous statistical techniques investigators use to reduce confounding in observational comparative effectiveness studies. Observational designs are therefore inadequate for definitively answering questions about comparative treatment effects of the various NOACs. Randomization is needed to assess causality, and RCTs are the gold standard for answering these questions. Observational data, whether employing RWD-or non-RWD, should be considered hypothesis-generating at best. The mere lack of funding for an RCT directly comparing NOACs has served as an 'excuse' to attempt to answer this question with observational data, and the fact that developers of the various NOACs have no incentive to fund RCTs comparing NOACs head-to-head has not been adequately dealt with by the clinical, patient, health system, and payer communities, as these head-to-head RCTs are exactly what is needed so that prescriptions of the drug with the best benefit-to-risk balance can be matched to the right patients. While the differences are likely to be modest, the large number of patients makes these comparative outcomes questions important to public health.
Contextualizing real-world data Figure 2 The hazard ratio for stroke/systemic embolism for non-vitamin K oral anticoagulants oral anticoagulants compared with warfarin and (B) the hazard ratio for major bleeding for non-vitamin K oral anticoagulants oral anticoagulants compared with warfarin are shown in observational and randomized studies. In both instances, a hazard ratio <1 indicates a lower risk of the outcome for non-vitamin K oral anticoagulants compared with warfarin. In observational studies, patients taking any dose of non-vitamin K oral anticoagulants were pooled; the data for patients taking 150 mg dabigatran twice daily in the pivotal randomized controlled trial of dabigatran is presented. ARISTOTLE, apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation; RE-LY, randomized evaluation of long-term anticoagulation therapy; ROCKET AF, rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; VKA, vitamin K antagonist; NOAC, non-vitamin K oral anticoagulant.
Resources currently allocated towards generating confounded comparative effectiveness studies could be targeted towards the generation of randomized data in a cost-effective way, through pragmatic RCTs. Stakeholders (regulatory agencies, professional societies, investigators, and patient groups) should work to develop streamlined, pragmatic RCTs comparing the safety and efficacy of the four available NOACs. There is clinical equipoise among the four NOACs, and all have well-established safety profiles from numerous traditional RCTs, obviating the need for adverse event reporting and site monitoring. The situation is ideal for this type of study, and the potential public health benefits of better understanding the comparative strengths and weaknesses of each medication could be considerable.
Conclusion
Real-world data is an important tool for answering critical clinical questions, but dividing data by source-into RWD and non-RWDis not, itself, an adequate framework for understanding the strengths and weaknesses of evidence. Instead, the focus should be placed both on data source and study design. Studies using different methodologies and data sources have strengths and weaknesses, which must be acknowledged when designing and conducting a study to answer a research question, as well as when reporting or interpreting the results of any given study. Observational studies incorporating RWD are best for answering questions regarding how a medication is used in clinical practice, and can sometimes be useful to measure outcomes in a cohort of patients taking a single medication. However, if investigators intend to compare outcomes between two or more medications, randomization is required to draw causal conclusions because studies employing observational designs are necessarily confounded.
When using observational study designs in treatment comparisons, whether involving RWD or non-RWD, investigators should understand and report limitations related to data source and study methodology in manuscripts and note these limitations when discussing study results with the medical and lay press. Medical journals should scrutinize manuscripts for appropriate reporting of observational results, including clear statements regarding limitations, replacement of the language of causation ('increased', 'effect', 'impact') with the language of association ('higher', 'association', 'correlated'), and avoidance of definitive conclusions. Both investigators and medical journals should reference studies' design and data source rather than data source alone in titles and abstracts ('observational real-world study' rather than 'real-world study'). The pharmaceutical industry should avoid the inappropriate use of observational studies for commercial and marketing purposes.
Most importantly, with the rise of pragmatic clinical trials, RCT need not imply non-RWD, and pragmatic clinical trials using RWD are needed to build the evidence base for countless decisions physicians are faced with each day, including which oral anticoagulant to choose for a given patient. Patients would be better served if rather than spreading limited resources across multiple groups performing comparative effectiveness studies using observational RWD, priority were given to collaborative efforts that seek to embed randomization into clinical practice in order to provide definitive answers to these key questions.
